vs

Side-by-side financial comparison of Cellebrite DI Ltd. (CLBT) and INSMED Inc (INSM). Click either name above to swap in a different company.

Cellebrite DI Ltd. is the larger business by last-quarter revenue ($292.2M vs $263.8M, roughly 1.1× INSMED Inc). Cellebrite DI Ltd. runs the higher net margin — -103.5% vs -124.5%, a 21.0% gap on every dollar of revenue. Cellebrite DI Ltd. produced more free cash flow last quarter ($60.8M vs $-264.2M). Over the past eight quarters, INSMED Inc's revenue compounded faster (86.9% CAGR vs 72.8%).

Cellebrite DI Ltd. is a digital forensics company headquartered in Petah Tikva, Israel that provides tools for law enforcement agencies as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Their flagship product series is the Cellebrite UFED.

Insmed Inc. is a global biopharmaceutical firm focused on developing and commercializing innovative therapies for patients with serious rare diseases that have high unmet medical needs. Its key offerings target pulmonary and endocrine rare disorders, serving markets across North America, Europe, and Asia Pacific.

CLBT vs INSM — Head-to-Head

Bigger by revenue
CLBT
CLBT
1.1× larger
CLBT
$292.2M
$263.8M
INSM
Higher net margin
CLBT
CLBT
21.0% more per $
CLBT
-103.5%
-124.5%
INSM
More free cash flow
CLBT
CLBT
$325.0M more FCF
CLBT
$60.8M
$-264.2M
INSM
Faster 2-yr revenue CAGR
INSM
INSM
Annualised
INSM
86.9%
72.8%
CLBT

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
CLBT
CLBT
INSM
INSM
Revenue
$292.2M
$263.8M
Net Profit
$-302.3M
$-328.5M
Gross Margin
84.6%
83.2%
Operating Margin
14.1%
-121.2%
Net Margin
-103.5%
-124.5%
Revenue YoY
152.6%
Net Profit YoY
-39.5%
EPS (diluted)
$-1.50
$-1.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBT
CLBT
INSM
INSM
Q4 25
$263.8M
Q3 25
$292.2M
$142.3M
Q2 25
$220.8M
$107.4M
Q1 25
$89.6M
$92.8M
Q4 24
$104.4M
Q3 24
$232.1M
$93.4M
Q2 24
$185.3M
$90.3M
Q1 24
$71.2M
$75.5M
Net Profit
CLBT
CLBT
INSM
INSM
Q4 25
$-328.5M
Q3 25
$-302.3M
$-370.0M
Q2 25
$36.9M
$-321.7M
Q1 25
$-71.4M
$-256.6M
Q4 24
$-235.5M
Q3 24
$-220.5M
Q2 24
$-95.2M
$-300.6M
Q1 24
$-40.6M
$-157.1M
Gross Margin
CLBT
CLBT
INSM
INSM
Q4 25
83.2%
Q3 25
84.6%
79.4%
Q2 25
84.1%
73.9%
Q1 25
85.2%
77.1%
Q4 24
75.0%
Q3 24
83.5%
77.3%
Q2 24
84.1%
76.8%
Q1 24
82.6%
76.9%
Operating Margin
CLBT
CLBT
INSM
INSM
Q4 25
-121.2%
Q3 25
14.1%
-257.1%
Q2 25
12.1%
-291.3%
Q1 25
10.3%
-267.3%
Q4 24
-220.6%
Q3 24
7.9%
-228.4%
Q2 24
11.7%
-319.8%
Q1 24
0.2%
-192.7%
Net Margin
CLBT
CLBT
INSM
INSM
Q4 25
-124.5%
Q3 25
-103.5%
-260.0%
Q2 25
16.7%
-299.5%
Q1 25
-79.7%
-276.4%
Q4 24
-225.5%
Q3 24
-236.0%
Q2 24
-51.4%
-332.8%
Q1 24
-57.0%
-208.1%
EPS (diluted)
CLBT
CLBT
INSM
INSM
Q4 25
$-1.55
Q3 25
$-1.50
$-1.75
Q2 25
$0.15
$-1.70
Q1 25
$-0.36
$-1.42
Q4 24
$-1.30
Q3 24
$-0.35
$-1.27
Q2 24
$-0.48
$-1.94
Q1 24
$-0.21
$-1.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBT
CLBT
INSM
INSM
Cash + ST InvestmentsLiquidity on hand
$191.7M
$1.4B
Total DebtLower is stronger
$546.8M
Stockholders' EquityBook value
$336.0M
$739.0M
Total Assets
$690.6M
$2.3B
Debt / EquityLower = less leverage
0.74×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBT
CLBT
INSM
INSM
Q4 25
$1.4B
Q3 25
$191.7M
$1.7B
Q2 25
$326.1M
$1.9B
Q1 25
$191.7M
$1.2B
Q4 24
$1.4B
Q3 24
$189.5M
$1.5B
Q2 24
$178.6M
$1.2B
Q1 24
$189.5M
$595.7M
Total Debt
CLBT
CLBT
INSM
INSM
Q4 25
$546.8M
Q3 25
$546.8M
Q2 25
$546.8M
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$971.8M
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
CLBT
CLBT
INSM
INSM
Q4 25
$739.0M
Q3 25
$336.0M
$945.6M
Q2 25
$408.4M
$1.2B
Q1 25
$336.0M
$99.2M
Q4 24
$285.4M
Q3 24
$34.2M
$483.4M
Q2 24
$-40.2M
$38.8M
Q1 24
$34.2M
$-464.8M
Total Assets
CLBT
CLBT
INSM
INSM
Q4 25
$2.3B
Q3 25
$690.6M
$2.4B
Q2 25
$787.4M
$2.5B
Q1 25
$690.6M
$1.8B
Q4 24
$2.0B
Q3 24
$532.9M
$2.1B
Q2 24
$556.6M
$1.8B
Q1 24
$532.9M
$1.2B
Debt / Equity
CLBT
CLBT
INSM
INSM
Q4 25
0.74×
Q3 25
0.58×
Q2 25
0.44×
Q1 25
11.31×
Q4 24
3.93×
Q3 24
2.01×
Q2 24
30.66×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBT
CLBT
INSM
INSM
Operating Cash FlowLast quarter
$66.2M
$-247.6M
Free Cash FlowOCF − Capex
$60.8M
$-264.2M
FCF MarginFCF / Revenue
20.8%
-100.1%
Capex IntensityCapex / Revenue
1.8%
6.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$172.1M
$-967.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBT
CLBT
INSM
INSM
Q4 25
$-247.6M
Q3 25
$66.2M
$-219.8M
Q2 25
$53.5M
$-205.6M
Q1 25
$10.0M
$-262.1M
Q4 24
$-196.0M
Q3 24
$58.2M
$-180.9M
Q2 24
$24.6M
$-123.0M
Q1 24
$12.5M
$-184.0M
Free Cash Flow
CLBT
CLBT
INSM
INSM
Q4 25
$-264.2M
Q3 25
$60.8M
$-222.2M
Q2 25
$47.5M
$-209.1M
Q1 25
$8.5M
$-272.2M
Q4 24
$-202.8M
Q3 24
$55.3M
$-184.6M
Q2 24
$21.0M
$-129.7M
Q1 24
$11.4M
$-188.7M
FCF Margin
CLBT
CLBT
INSM
INSM
Q4 25
-100.1%
Q3 25
20.8%
-156.1%
Q2 25
21.5%
-194.6%
Q1 25
9.5%
-293.2%
Q4 24
-194.1%
Q3 24
23.8%
-197.6%
Q2 24
11.3%
-143.6%
Q1 24
16.0%
-250.0%
Capex Intensity
CLBT
CLBT
INSM
INSM
Q4 25
6.3%
Q3 25
1.8%
1.7%
Q2 25
2.7%
3.2%
Q1 25
1.7%
10.8%
Q4 24
6.5%
Q3 24
1.3%
3.9%
Q2 24
1.9%
7.5%
Q1 24
1.5%
6.2%
Cash Conversion
CLBT
CLBT
INSM
INSM
Q4 25
Q3 25
Q2 25
1.45×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLBT
CLBT

Subscription services$197.2M67%
Term-license$60.8M21%
Professional services$23.2M8%
Other non-recurring$11.0M4%

INSM
INSM

Segment breakdown not available.

Related Comparisons